Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 06, 2026
Equinor ASA (EQNR): Q1 2026 Earnings Beat Expectations with Record Production

Equinor ASA (EQNR): Q1 2026 Earnings Beat Expectations with Record Production

Key Takeaways

  • Equinor ASA reported adjusted operating income of $9.77 billion and adjusted net income of $3.70 billion in Q1 2026, surpassing consensus expectations for adjusted EPS of $1.01 with $1.48.
  • Total equity production hit a record 2,313 thousand barrels of oil equivalent per day (mboe/d), up 9% year-over-year.
  • Net operating income was $8.78 billion, slightly below Q1 2025's $8.87 billion due to lower European gas prices.
  • Cash flow from operations after taxes paid reached $6.02 billion; organic capital expenditures totaled $3.04 billion.
  • Declared Q1 cash dividend of $0.39 per share; second tranche of 2026 share buy-back program up to $375 million to start post-AGM.
  • Seven commercial discoveries on the Norwegian Continental Shelf (NCS).

Q1 Earnings in Context

I've been following Equinor ASA (EQNR), the major energy player in oil, gas, and renewables, through these turbulent global markets. Their Q1 2026 results just came out, and they offer a clear picture of the company's operational strength. Record production levels helped offset weaker gas prices, which is no small feat. For investors like us, this report highlights Equinor's disciplined approach to maintaining high output on the Norwegian Continental Shelf (NCS) while pushing forward internationally and in renewables. Geopolitical tensions have lifted liquids prices lately, supporting the numbers, but European gas prices are something I'm watching closely. The robust cash flows here continue to back solid shareholder returns through dividends and buybacks, making this a key update for gauging the 2026 outlook in a shifting energy landscape.

Breaking Down the Reported Results

Equinor ASA (EQNR) posted strong Q1 2026 figures, with adjusted operating income at $9.77 billion, beating the consensus of around $9.00 billion from 23 analysts. Adjusted net income reached $3.70 billion, or $1.48 per share on an adjusted basis—well ahead of the $1.01 estimate.

Reported net operating income came in at $8.78 billion, a slight dip from $8.87 billion in Q1 2025, mainly due to lower realized European gas prices of $12.9 per mmbtu and negative derivative effects. This was partly balanced by higher liquids prices at $78.6 per barrel and, importantly, record production. Net income was $3.10 billion. Standout metrics included total equity production up 9% to a record 2,313 mboe/d, fueled by 10% growth on the NCS, US onshore gas, and new assets like Adura and Bacalhau. Cash flow from operations before taxes and working capital hit $10.29 billion, dropping to $6.02 billion after taxes. Organic capex was $3.04 billion, under the $3.22 billion consensus.

Segments performed well too, with solid results in Marketing, Midstream & Processing (MMP) trading and steady power generation at 1.39 TWh. From what I see, Equinor delivered on profitability and efficiency even against market pressures. I also checked this using Tickeron’s AI Screener to compare how EQNR stacks up against peers on key metrics.

Market Reaction and What's Driving Sentiment

EQNR shares closed at $41.36 on May 5, 2026, up 77.59% year-to-date on energy sector momentum. Pre-market on May 6 showed a 9.45% decline to $37.43, likely reflecting the modest year-over-year drop in net operating income and worries about European gas prices, despite the beats on adjusted figures and production. That said, sentiment stays constructive around operational execution and capital returns, though commodity swings and geopolitics add caution.

Why I Use Tickeron's AI Screener in My Analysis

In my research process, Tickeron’s AI Screener has become a go-to tool for efficiently scanning stocks and ETFs. It lets me filter based on technical patterns, fundamentals, trends, volatility, and AI signals across thousands of names, using criteria like industry, market cap, indicators, and performance. This helps spot trade ideas, breakouts, and opportunities faster than manual methods. One thing that stands out is how it streamlines comparing EQNR to the field—I've found it invaluable for sharpening my edge without the time sink.

Looking Ahead: Outlook and Factors to Track

Equinor stuck to its production growth and shareholder return plans after Q1. The $0.39 per share Q1 dividend matches prior guidance and pays out post the May 12, 2026, AGM. The second tranche of the $1.5 billion 2026 share buy-back—up to $375 million—starts after the AGM and runs through July 20, 2026, covering redemptions for the Norwegian State.

Exploration remains a highlight, with seven NCS discoveries this quarter amid high drilling. Keep an eye on international updates like Raia gas in Brazil and renewables such as the Esquina do Vento wind project, where construction starts in 2026. US output, particularly Appalachia gas, should keep driving growth.

Commodity prices matter a lot: liquids lifted Q1, but soft European gas and geopolitical volatility could squeeze margins. Net debt to capital employed improved to 15.3%, giving good flexibility. Q2 results on July 22, 2026, and the Capital Markets Day on June 15 will provide more on FY2026 goals, including long-term production toward 2035.

In my view, Equinor's emphasis on cost control, portfolio tweaks, and the energy transition keeps it well-positioned.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: EQNR

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Aroon Indicator for EQNR shows an upward move is likely

EQNR's Aroon Indicator triggered a bullish signal on September 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 214 similar instances where the Aroon Indicator showed a similar pattern. In 163 of the 214 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 70 cases where EQNR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

EQNR moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where EQNR advanced for three days, in 216 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The 10-day RSI Indicator for EQNR moved out of overbought territory on September 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 18 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.

The Momentum Indicator moved below the 0 level on September 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EQNR as a result. In 47 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for EQNR turned negative on September 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EQNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.

EQNR broke above its upper Bollinger Band on September 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 28, placing this stock better than average.

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.327) is normal, around the industry mean (1.887). P/E Ratio (11.455) is within average values for comparable stocks, (16.521). Projected Growth (PEG Ratio) (1.109) is also within normal values, averaging (1.088). Dividend Yield (0.036) settles around the average of (0.035) among similar stocks. P/S Ratio (0.972) is also within normal values, averaging (3.764).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. EQNR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share) (NYSE:PBR), BP plc (NYSE:BP), Suncor Energy (NYSE:SU), YPF Sociedad Anonima (NYSE:YPF).

Industry description

Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.

Market Cap

The average market capitalization across the Integrated Oil Industry is 124.33B. The market cap for tickers in the group ranges from 63.2K to 668.27B. XOM holds the highest valuation in this group at 668.27B. The lowest valued company is CRRDF at 63.2K.

High and low price notable news

The average weekly price growth across all stocks in the Integrated Oil Industry was 3%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 4%. PBR experienced the highest price growth at 17%, while TTE experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Integrated Oil Industry was 61%. For the same stocks of the Industry, the average monthly volume growth was 65% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 40
P/E Growth Rating: 50
Price Growth Rating: 47
SMR Rating: 55
Profit Risk Rating: 27
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
EQNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which explores, produces, transports, refines and markets petroleum and petroleum-derived products

Industry IntegratedOil

Industry
Integrated Oil
Address
Forusbeen 50
Phone
+47 51990000
Employees
24140
Web
https://www.equinor.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
Equinor ASA (EQNR): Q1 2026 Earnings Beat Expectations with Record Production